Related Experiment Videos
Botulinum toxin A in management of cerebral palsy
R Calderon-Gonzalez1, R Calderon-Sepulveda, M Rincon-Reyes
1Department of Pediatric Neurology, Children and Adolescents Neurological Center, Monterrey, Mexico.
Insights
Botulinum toxin A injections effectively reduced muscle hypertonia and contractures in children with cerebral palsy. This treatment improved range of motion and motor function, offering a new therapeutic option.
Area of Science:
- Neurology
- Pediatrics
- Rehabilitation Medicine
Background:
- Cerebral palsy often causes muscle hypertonia and contractures, limiting motor function.
- Conventional physical therapy may not sufficiently address these impairments in some children.
- Botulinum toxin A is a potential therapeutic agent for targeted muscle relaxation.
Purpose of the Study:
- To evaluate the efficacy of local botulinum toxin A injections in managing muscle hypertonia and contractures in pediatric cerebral palsy patients.
- To assess the impact of these injections on joint range of motion and overall motor function.
Main Methods:
- An open-label, ABA (baseline-treatment-posttreatment) study design was employed.
- Fifteen children with cerebral palsy and limb deformities underwent intramuscular botulinum toxin A injections.
- Muscle tone was assessed using the modified Ashworth scale, and range of motion was measured with a manual goniometer.
Main Results:
- Significant reductions in muscle hypertonia (P < .01) and significant increases in range of motion (P < .001) were observed post-injection.
- Functional improvements included decreased scissoring, improved knee extension, and enhanced heel-strike capability.
- All patients demonstrated positive responses to the treatment.
Conclusions:
- Intramuscular botulinum toxin A injections are effective in decreasing muscle tone and contractures in children with cerebral palsy.
- The treatment leads to increased range of motion and improved motor function.
- Botulinum toxin A offers a valuable therapeutic option for selected pediatric cerebral palsy patients.
Abstract:
The efficacy of local injection of botulinum toxin A in selected skeletal muscles to relieve muscle hypertonia and muscle contracture, and increase range of motion in children with cerebral palsy was studied in an open ABA (baseline-treatment-posttreatment phase) type of study. The first 6 months were the baseline phase, the day of injection the treatment phase, and the next 6 months the posttreatment phase. The patients acted as their own controls. Fifteen children with cerebral palsy (mean age: 6 years, 8 months) were included in the study. All had limb deformities associated with non-fixed joint contractures that had not responded to physical therapy. Clinical assessment of passive and active muscle tone was performed using a modified Ashworth scale. The range of motion to passive movement was measured with a manual goniometer. Botulinum toxin was injected directly into the muscle at several sites. The postinjection scores of muscle hypertonia were significantly lower (P < .01) and the range-of-motion values demonstrated a significant increase (P < .001). Functional improvement was measured by decreased scissoring on standing in all 6 children with adductor muscles injected; all 6 children with knee flexor muscles injected were able to straighten the knees. The 3 children with injected gastrocnemius muscles were able to achieve heel-strike while bare-footed. The study provides evidence that the intramuscular injection of botulinum toxin A in selected skeletal muscles decreases muscle tone and contractures, and increases range of motion and motor function.